Evaluate the effect of posterolateral approach (PLA) in reducing surgical trauma and postoperative inflammatory stress

Postoperative inflammatory stress in small incision total hip arthroplasty with posterior lateral approach

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN10942792

Enrollment

Registered

2024-09-14

Start date

2022-04-02

Completion date

Unknown

Last updated

2024-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Evaluation after small incision total hip arthroplasty with posterior lateral approach Musculoskeletal Diseases

Interventions

The sample size was calculated based on a power analysis to detect a significant difference in postoperative inflammatory stress injury, with an expected effect size of 0.5, a power of 0.8, and a sign

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Meet the osteonecrosis of femoral head (ONFH) diagnostic criteria confirmed by the participating hospital 2. Meet the surgical indications for total hip arthroplasty (THA) and scheduled to be operated in the participating hospital with complete medical records 3. Normal preoperative examinations

Exclusion criteria

Exclusion criteria: 1. Malignant tumor 2. Coagulation dysfunction 3. Immune deficiency 4. Serious dysfunction of organs such as the heart, brain, liver, and kidneys 4. Mental illness, abnormal intelligence, or inability to communicate normally

Design outcomes

Primary

Measure	Time frame
1. Pain measured using a Visual Analogue Scale (VAS) before surgery, 1 week after surgery, and one month after surgery 2. Hip function measured using the Hospital for Special Surgery (HSS) score before surgery, 1 week after surgery, and one month after surgery 3. The white blood cell count (WBC), neutrophil-lymphocyte ratio (NLR), and macrophages (mø) measured using an automatic blood cell analyzer (Model: Sysmex XN-1000, Sysmex Corporation, Kobe, Japan). High-sensitivity C-reactive protein (hs-CRP) levels measured with a high-sensitivity immunoturbidimetric assay using the Cobas c 702 module (Roche Diagnostics, Basel, Switzerland). Interleukin-6 (IL-6) measured by enzyme-linked immunosorbent assay (ELISA) using kits ordered from Beijing Xingyi Yachuang Biotechnology Co., Ltd., with readings obtained using the Bio-Rad iMark microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). All measurements were taken 1 week after surgery. 4. Deep Vein Thrombosis (DVT), with DVT diagnostic criteria: swelling, pigmentation, pain in the affected area, weak or no venous blood flow signal on ultrasonography, extremely low venous lumen echo, and irregular pulse Doppler spectrum measured using data collected from patient medical records one month after surgery	—

Measure

Time frame

1. Pain measured using a Visual Analogue Scale (VAS) before surgery, 1 week after surgery, and one month after surgery 2. Hip function measured using the Hospital for Special Surgery (HSS) score before surgery, 1 week after surgery, and one month after surgery 3. The white blood cell count (WBC), neutrophil-lymphocyte ratio (NLR), and macrophages (mø) measured using an automatic blood cell analyzer (Model: Sysmex XN-1000, Sysmex Corporation, Kobe, Japan). High-sensitivity C-reactive protein (hs-CRP) levels measured with a high-sensitivity immunoturbidimetric assay using the Cobas c 702 module (Roche Diagnostics, Basel, Switzerland). Interleukin-6 (IL-6) measured by enzyme-linked immunosorbent assay (ELISA) using kits ordered from Beijing Xingyi Yachuang Biotechnology Co., Ltd., with readings obtained using the Bio-Rad iMark microplate reader (Bio-Rad Laboratories, Hercules, CA, USA). All measurements were taken 1 week after surgery. 4. Deep Vein Thrombosis (DVT), with DVT diagnostic criteria: swelling, pigmentation, pain in the affected area, weak or no venous blood flow signal on ultrasonography, extremely low venous lumen echo, and irregular pulse Doppler spectrum measured using data collected from patient medical records one month after surgery

—

Secondary

Measure	Time frame
The following secondary outcome measure variables will be collected using patient medical notes after surgery: 1. Incision length 2. Operation time 3. Intraoperative and postoperative blood transfusion	—

Countries

China

Contacts

Public ContactYiping Li

liyiping_yp@126.com+8613757442401

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026